Статья
СНИЖЕНИЕ СЕРДЕЧНО-СОСУДИСТОГО РИСКА ПРИ САХАРНОМ ДИАбЕТЕ 2 ТИПА НА ФОНЕ ЛЕЧЕНИЯ ЛИРАГЛУТИДОМ И ЕГО ПЛЕЙОТРОПНЫЙ ЭФФЕКТ — МАНДАТ ДЛЯ КАРДИОЛОГА И ТЕРАПЕВТА
Результаты целого ряда крупных исследований (LEADER, EMPA-REG, CANVAS) убедительно доказывают целесообразность применения современных сахароснижающих препаратов для успешного управления кардиоваскулярным риском у пациентов с сахарным диабетом (СД) 2 типа. В данной работе всесторонне рассмотрены и проанализированы возможные механизмы и преимущества снижения сердечно-сосудистого риска у пациентов с СД 2 типа при назначении агониста глюкагон-подобного пептида 1 лираглутида (Виктоза®).
1. Sattar N, Petrie MC, Zinman B, et al. Novel diabetes drugs and the cardiovascular specialist. Journal of the American College of Cardiology. 2017 May 22; 69 (21): 2646-56. DOI: 10.1016/j.jacc.2017.04.014.
2. www.siditalia.it/news/1229-26-07-2016-position-statement-sid-farmaciipoglicemizzanti-malattie-cardiovascolari-e-renali.
3. Lehmann R, Bianda T, Brändle M, et al. Arbeitsgruppe der SGED/SSED Empfehlungen der SGED/SSED: Massnahmen zur Blutzuckerkontrolle bei Patien-ten mit Diabetes mellitus Type 2. http://sgedssed.ch/fileadmin/files/6_empfehlungen_fachpersonen/61_richtlinien_fachaerzte/SGED_Empfehlung_BZ-Kontrolle_T2DM_Finale_Version_12_korr_17.10.16.pdf.
4. Nasjonal faglig retningslinje for diabetes. Nasjonal faglig retningslinje for diabetes Sist oppdatert 20.9.2016. https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=8&ved=0ahUKEwiFjdXg7IjVAhUoDZoKHRKCAR8QFghVMAc&url=https%3A%2F%2Fmitt.uib.no%2Fcourses%2F1966%2Ffiles%2F213291%2Fdownload%3Fdownload_frd%3D1&usg=AFQjCNGKGkmUfeZtHrmv41XGmwYnNk7VBw&cad=rjt.
5. Policies, Guidelines, and Consensus Statements Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Can J Diabetes 2016; 40: 484-6.
6. Landgraf R, Kellerer M, Fach E, et al. Praxisempfehlungen DDG/DGIM. Diabetologie und Stoffwechsel. 2016 Oct;11 (S 02): S117-29.
7. Clinical guidelines. Algorithms of specialized medical care to patients with diabetes. Ed. Dedova II, Shestakova MV, Mayorova A. Yu. Diabetes mellitus 2017; 20 (1S): 1-112. (In Russ.) Клинические рекомендации “Алгоритмы специализированной медицинской помощи больным сахарным диабетом”, под ред. Дедова И. И., Шестаковой М. В., Майорова А. Ю. Сахарный диабет 2017; 20 (1S): 1-112. DOI: 10.14341/DM20171S8.
8. Editorial a. The possibility of reducing cardiovascular risk in patients with diabetes mellitus type 2. Russian Journal of Cardiology. 2017; 9: 99-103. (In Russ.) Редакционная с. Возможности снижения сердечно-сосудистых рисков у пациентов с сахарным диабетом 2 типа. Российский кардиологический журнал. 2017; 9: 99-103. DOI: 10.15829/1560-4071-2017-9-99-103.
9. www.who.int
10. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-7.
11. Neaton JD, Wentworth DN, Cutler J, et al. Risk factors for death from different types of stroke. Multiple Risk Factor Intervention trial Research Group. Ann Epidemiol 1993; 3: 493-9.
12. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet. 2010 Jun 26; 375 (9733): 2215-22.
13. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation, 2015.
14. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U. S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
15. Haffner SM, Lehto S, Ronnemaa T. Mortality from coronary artery disease in subject with type 2 diabetes and nondiabetic subjects with and without myocardial infarction. N Engl J Med 1998; 339: 229-34.
16. Rydén L, Grant P, Anker S, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Russian Journal of Cardiology. 2014; 3 (107): 7-61. (In Russ.) Rydén L, Grant P, Anker S, et al. Рекомендации по диабету, предиабету и сердечно-сосудистым заболеваниям. EASD/ESC. Рабочая группа по диабету, предиабету и сердечно-сосудистым заболеваниям Европейского общества кардиологов (ESC) в сотрудничестве с Европейской ассоциацией по изучению диабета (EASD). Российский кардиологический журнал 2014, 3 (107): 7-61.
17. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, N Engl J Med 2016; 375: 311-22. DOI: 10.1056/NEJMoa1603827.
18. Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-25.
19. Ettehad D, Emdin CA, Kiran A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet 387.10022 (2016): 957-67. DOI: 10.1016/S0140-6736(15)01225-8.
20. Higgins M, Kannel W, Garrison R, et al. Hazards of Obesity-the Framingham Experience. Journal of Internal Medicine. 1987 Jan 12; 222 (S723): 23-36.
21. Bouchi R, Nakano Y, Fukuda T, et al. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Endocrine journal. 2017; 64 (3): 269-81.
22. Courrèges JP, Vilsbøll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabetic Medicine. 2008 Sep 1; 25 (9): 1129-31.
23. Díaz-Soto G, de Luis DA, Conde-Vicente R, et al. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with type 2 diabetes: a prospective study. Diabetes research and clinical practice. 2014 Apr 1; 104 (1): 92-6.
24. Kim SH, Abbasi F, Lamendola C, et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013 Oct 1; 36 (10): 3276-82.
25. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell metabolism. 2016 Jul 12; 24 (1): 15-30.
26. Thorens B, Porret A, Bühler L, et al. Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor. Diabetes. 1993 Nov 1; 42 (11): 1678-82.
27. Gutzwiller JP, Göke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999 Jan 1; 44 (1): 81-6.
28. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. The Journal of Clinical Endocrinology & Metabolism. 1995 Mar 1; 80 (3): 952-7.
29. Hansen L, Deacon CF, Ørskov C, et al. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999 Nov 1; 140 (11): 5356-63.
30. Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. Journal of Biological Chemistry. 1992 Apr 15; 267 (11): 7402-5.
31. Falko JM, Crockett SE, Cataland S, et al. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. The Journal of Clinical Endocrinology & Metabolism. 1975 Aug 1; 41 (2): 260-5.
32. McIntyre NE, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. The Journal of Clinical Endocrinology & Metabolism. 1965 Oct 1; 25 (10): 1317-24.
33. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2016; 18: 203-16.
34. Du Q, Wang YJ, Yang S, et al. Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Adv Ther 2014; 31: 1182-95.
35. Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 3.
36. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care 2016; 39 (2): 222-30.
37. Zavattaro M, Caputo M, et al. One-year treatment with liraglutide improved renal functionin patients with type 2 diabetes: a pilot prospective study. Endocrine 2015; 50 (3): 620-6.
38. American Diabetes Association Standards of Medical Care in Diabetes, 2017. Diabetes Care 2017; 40 (Suppl 1): 1-142. 1-142